ESPE2024 Poster Category 3 Late Breaking (83 abstracts)
Evaluation of Effects of Using Mobile Treatment Reminder GroConnect on Treatment Compliance and Treatment Response in Patients Receiving Growth Hormone Treatment – Preliminary Results
Semra Çetinkaya 1 , Tuğçe Kandemir 2 , Deniz Kızılay Özalp 3 , Gülay Karagüzel 4 , Doğa Türkkahraman 5 , Erdal Eren 6 , Melek Yıldız 2 , Nihal Gül Uslu 3 , Samim Özen 3 , Emine Ayça Cimbek 4 , Ceyhun Tıkız 5 , Hatice Nursoy 6 & Feyza Darendeliler 2
1University Of Health Science, Dr Sami Ulus Children’s Health and Diseases, Health Implementation and Research Center, Clinics of Pediatric Endocrinology, Ankara, Turkey. 2Istanbul University, Istanbul Faculty of Medicine, Department of Pediatric Endocrinology, Istanbul, Turkey. 3Ege University, School of Medicine, Department of Pediatric Endocrinology, İzmir, Turkey. 4Karadeniz Technical University, Faculty of Medicine, Department of Pediatric Endocrinology, Trabzon, Turkey. 5University Of Health Science, Antalya Training and Research Hospital, Clinics of Pediatric Endocrinology, Antalya, Turkey. 6Uludağ University, Faculty of Medicine, Department of Pediatric Endocrinology, Bursa, Turkey
It is known that treatment reminder digital applications improve treatment compliance & response & healthcare expenses. Groconnect (mobile reminder) application is used by patients receiving growth hormone treatment (GHt), with its injection alarm/reminder/informative videos. Here, our three month preliminary data from our one-year follow-up study (aims to determine the effects of GroConnect use on treatment compliance & treatment response) is presented.
Material & Method: Childrens & adolescents from six different centers (receiving GHt for at least one year) and were about to receive new treatment, aged between 1-18 years (not use chronic medication) were included. They were requested to download the GroConnect ('Albert Health') to their mobile phones, register and fill out the login survey information. Group-1: Newly initiated GHt, Group-1a: Using GroConnect, Group-1b: Not using GroConnect. Group-2: Childrens & adolescents who have been receiving GHt for at least one year (±3 months) who completed the initial survey but did not activate the mobile reminder in the first six months, then activated it in the last six months. Study data entries & evaluations was done by the same researcher from each center. A one-year follow-up of the cases was planned. Demographic data/diagnoses/injection compliance/information about injection/educational resources/treatment durations/reasons for skipping injections/anthropometric data/treatment responses were recorded. The study received independent PfizerCyberGrant support (Number: 87847537).
Results: 167 cases from six centers, all groups were included (n:50 in Group-1, n:107 inGroup-2, n:21 in Group-1a & n:8 in Group-1b with 3-month follow-up, n:67 in Group-2). Among childrens & adolescents (n:28) who used digital reminders for an average of 3± 0.5months (median age: 10.2), previour to the study, we found that 25% of the cases used an alarm system as a medication time reminder. Childrens & adolescents entered the digital application 3703 times during study period (~1.2 entries/per day, 71.8% in the evening). They marked have been taken the medicine after the reminder alert. 14% of the subjects set a water drinking reminder. They received 428 notifications (on drug addition/training/application information), 232 of them were read (54% read rate). At the beginning, 62% of the cases declared that they had not missed any injections in the last month (100% compliance). However, by the end of the third month, this rate increased to 85%. While the 3-month mean growth velocity was 2.73cm in Group-1, it was 2.51cm in Group-2. The number of times the subjects entered the daily GroConnect increased over time. As a result, according to our preliminary study report; we predict that GroConnect increase treatment compliance/treatment response/support users with interim notifications in areas such as education and application, and can be an integral part of medical treatment.
Acknowledgements: Selahattin Çolakoğlu, Zeynep Pelin Polat, Yasemin Arıt (Albert Health Ltd, Clinical Development & Research, Istanbul, Türkiye), Furkan Erdoğan (Pfizer, Istanbul, Türkiye).
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more